Approaches to treat immune hot, altered and cold tumours with combination immunotherapies

Nature Reviews Drug Discovery, Journal Year: 2019, Volume and Issue: 18(3), P. 197 - 218

Published: Jan. 4, 2019

Language: Английский

---

Cancer immunotherapy: the beginning of the end of cancer?

BMC Medicine, Journal Year: 2016, Volume and Issue: 14(1)

Published: May 5, 2016

These are exciting times for cancer immunotherapy. After many years of disappointing results, the tide has finally changed and immunotherapy become a clinically validated treatment cancers. Immunotherapeutic strategies include vaccines, oncolytic viruses, adoptive transfer ex vivo activated T natural killer cells, administration antibodies or recombinant proteins that either costimulate cells block so-called immune checkpoint pathways. The recent success several immunotherapeutic regimes, such as monoclonal antibody blocking cytotoxic lymphocyte-associated protein 4 (CTLA-4) programmed cell death 1 (PD1), boosted development this modality, with consequence new therapeutic targets schemes which combine various immunological agents now being described at breathtaking pace. In review, we outline some main in (cancer cellular immunotherapy, blockade, viruses) discuss progress synergistic design immune-targeting combination therapies.

Language: Английский

---

Cold Tumors: A Therapeutic Challenge for Immunotherapy

Frontiers in Immunology, Journal Year: 2019, Volume and Issue: 10

Published: Feb. 7, 2019

Therapeutic monoclonal antibodies targeting immune checkpoints (ICPs) have changed the treatment landscape of many tumors. However, response rate remains relatively low in most cases. A major factor involved initial resistance to ICP inhibitors is lack or paucity tumor T cell infiltration, characterizing so-called "cold tumors". In this review, we describe main mechanisms absence including antigens, defect antigen presentation, activation and deficit homing into bed. We discuss then different therapeutic approaches that could turn cold hot way, specific therapies are proposed according their mechanism action. addition, "supra-physiological" therapies, such as recruiting bispecific Chimeric Antigen Receptor (CAR) cells, may be active regardless involved, especially MHC class I negative The determination factors implicated preexisting infiltration crucial for development adapted algorithms treatments

Language: Английский

---

A Review of Cancer Immunotherapy: From the Past, to the Present, to the Future

Current Oncology, Journal Year: 2020, Volume and Issue: 27(12), P. 87 - 97

Published: April 1, 2020

Compared with previous standards of care (including chemotherapy, radiotherapy, and surgery), cancer immunotherapy has brought significant improvements for patients in terms survival quality life. Immunotherapy now firmly established itself as a novel pillar care, from the metastatic stage to adjuvant neoadjuvant settings numerous types. In this review article, we highlight how history paved way discoveries that are part standard care. We also current pitfalls limitations checkpoint research fields personalized vaccines, autoimmunity, microbiome, tumour microenvironment, metabolomics is aiming solve those challenges.

Language: Английский

---

The future of cancer immunotherapy: microenvironment-targeting combinations

Cell Research, Journal Year: 2020, Volume and Issue: 30(6), P. 507 - 519

Published: May 28, 2020

Abstract Immunotherapy holds the potential to induce durable responses, but only a minority of patients currently respond. The etiologies primary and secondary resistance immunotherapy are multifaceted, deriving not from tumor intrinsic factors, also complex interplay between cancer its microenvironment. In addressing frontiers in clinical immunotherapy, we describe two categories approaches design novel drugs combination therapies: first involves direct modification tumor, while second indirectly enhances immunogenicity through alteration By systematically factors that mediate resistance, able identify mechanistically-driven improve outcomes.

Language: Английский

---

Integrating oncolytic viruses in combination cancer immunotherapy

Nature reviews. Immunology, Journal Year: 2018, Volume and Issue: 18(8), P. 498 - 513

Published: May 9, 2018

Language: Английский

---

Autophagy, Inflammation, and Immunity: A Troika Governing Cancer and Its Treatment

Cell, Journal Year: 2016, Volume and Issue: 166(2), P. 288 - 298

Published: July 1, 2016

Language: Английский

---

Oncolytic Viruses in Cancer Treatment

JAMA Oncology, Journal Year: 2016, Volume and Issue: 3(6), P. 841 - 841

Published: July 21, 2016

Oncolytic viruses (OVs) are emerging as important agents in cancer treatment. offer the attractive therapeutic combination of tumor-specific cell lysis together with immune stimulation, therefore acting potential situ tumor vaccines. Moreover, OVs can be engineered for optimization selectivity and enhanced stimulation readily combined other agents. The effectiveness has been demonstrated many preclinical studies recently humans, US Food Drug Administration approval oncolytic herpesvirus talimogene laherparepvec advanced melanoma, a major breakthrough field. Thus, OV approach to therapy is becoming more interesting scientists, clinicians, public. main purpose this review give basic overview clinical development provide description current status trials.In 2016 approximately 40 trials recruiting patients, using range multiple types. There also planning stages. Therefore, we now most active period history several currently being tested additional derivatives. In trials, there number specific areas that should considered, including viral pharmacokinetics pharmacodynamics, toxic effects, monitoring patients' status. Clinical increasingly focused on their stimulatory properties, which may work synergistically checkpoint inhibitors strategies treatment human cancer.Oncolytic an area research. ability these harness antitumor immunity appears key success. Combinatorial blockade have started results awaited great interest.

Language: Английский

---

Cancer vaccines as promising immuno-therapeutics: platforms and current progress

Journal of Hematology & Oncology, Journal Year: 2022, Volume and Issue: 15(1)

Published: March 18, 2022

Abstract Research on tumor immunotherapy has made tremendous progress in the past decades, with numerous studies entering clinical evaluation. The cancer vaccine is considered a promising therapeutic strategy of solid tumors. Cancer stimulates anti-tumor immunity antigens, which could be delivered form whole cells, peptides, nucleic acids, etc . Ideal vaccines overcome immune suppression tumors and induce both humoral cellular immunity. In this review, we introduced working mechanism summarized four platforms for development. We also highlighted research vaccines, especially focusing their application efficacy, might hopefully facilitate future design vaccine.

Language: Английский

---

Emerging Concepts for Immune Checkpoint Blockade-Based Combination Therapies

Cancer Cell, Journal Year: 2018, Volume and Issue: 33(4), P. 581 - 598

Published: April 1, 2018

Language: Английский

---